Sight Sciences reports recurring developments as an eyecare technology company developing and commercializing interventional ophthalmic devices for glaucoma and dry eye disease. Its news commonly covers financial results and guidance, segment trends in Interventional Glaucoma and Interventional Dry Eye, and clinical data for the OMNI Surgical System and TearCare System.
Company updates also address investor conference participation, intellectual property matters involving interventional glaucoma patents, and product positioning across minimally invasive glaucoma surgery and evaporative dry eye treatment. News about SGHT centers on commercialization, reimbursement-sensitive procedure adoption, clinical evidence, and operating performance in its ophthalmic device portfolio.
Sight Sciences (Nasdaq: SGHT) plans to present at two upcoming healthcare investor conferences, both in New York.
The Stifel 2026 Healthcare Conference presentation is November 11, 2026, at 7:00 am PT / 10:00 am ET. The Piper Sandler 38th Annual Healthcare Conference presentation is December 2, 2026, at 12:00 pm PT / 3:00 pm ET. Live and archived webcasts of the fireside chats will be available on the company’s investor website.
Sight Sciences (SGHT) announced that CMS established a direct practice expense supply code for the single-use TearCare SmartLids component.
Supply code SD397 carries an assigned price of $1,000, effective January 1, 2027, under the CY 2027 Medicare Physician Fee Schedule Final Rule. The company believes the valuation can support more transparent and consistent reimbursement for TearCare procedures over time.
The related procedure code, CPT 0563T, remains carrier-priced. The new supply code does not establish a national Medicare payment rate or separate reimbursement for SmartLids; payment remains subject to applicable payer coverage and reimbursement policies.
Sight Sciences (Nasdaq: SGHT) reported third-quarter 2026 revenue of $24.9 million and raised its full-year revenue guidance. Revenue rose 25% year over year. Interventional Glaucoma revenue increased 7% to $21.0 million; Interventional Dry Eye revenue reached $3.9 million, versus $0.2 million a year earlier and $2.7 million in the second quarter. Net loss narrowed to $6.8 million, or $0.12 per share, from $8.2 million, or $0.16 per share.
The company now expects 2026 revenue of $92 million to $93 million, up from $88 million to $92 million, and maintained adjusted operating expense guidance of $92 million to $94 million. Quarterly gross margin was 85.9%, versus 86.4% a year earlier. Cash usage fell 74% to $2.4 million, leaving $77.4 million in cash and equivalents at September 30; debt principal remained $40.0 million. Sight Sciences also launched its OMNI Ultra Surgical System.
Sight Sciences (SGHT) will report its third-quarter 2026 financial results after the market close on November 4, 2026. The quarter ended September 30, 2026. Management will discuss the results on a conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern. A live and archived webcast will be available on the company's investor website, with replay access for at least 90 days.
Sight Sciences (SGHT) announced commercial availability of the OMNI Ultra Surgical System, the latest generation of its glaucoma surgery platform. The implant-free device enables single-pass canaloplasty followed by trabeculotomy, procedures that address resistance in the eye’s fluid drainage pathway. It can be used alone or with cataract surgery in adults with primary open-angle glaucoma.
OMNI Ultra will be featured at the AAO annual meeting, October 9–12 in New Orleans. Sight Sciences will also preview Clearance Assistant Plus, a tool for meibomian gland expression and eyelid debridement used with the TearCare System.
Sight Sciences (Nasdaq: SGHT) announced that its management will present at the Morgan Stanley Global Healthcare Conference in New York, NY. The presentation is scheduled for Tuesday, September 15, 2026, at 6:15 a.m. PT / 9:15 a.m. ET. Interested investors can access a live and archived webcast of the fireside chat via the Investors section of the Sight Sciences website.
Sight Sciences (Nasdaq: SGHT) announced that, effective August 18, 2026, the U.S. FDA updated the TearCare System Indications for Use to specify that it is a thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used with manual gland expression.
With this expanded indication, TearCare becomes the first and only MGD treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease. The updated clearance also incorporates optional debridement as part of the system and emphasizes a clinically meaningful endpoint focused on restoring gland function.
Sight Sciences (Nasdaq: SGHT) reported second quarter 2026 revenue of $23.4 million, up 20% year over year, with Interventional Glaucoma at $20.7 million (+8%) and record Interventional Dry Eye at $2.7 million (+704%). Gross profit was $21.4 million and reported gross margin 91%, or 86% excluding a $1.4 million tariff refund benefit.
Total operating expenses fell 11% to $25.3 million, and net loss improved to $4.4 million from $11.9 million, with net loss per share of $0.08. Cash and cash equivalents were $79.8 million with total long-term debt of $40.0 million; cash usage declined 28% to $5.2 million, or $1.4 million excluding non-recurring items. The company raised its full-year 2026 revenue guidance to $88–$92 million and lowered adjusted operating expense guidance to $92–$94 million. Additional highlights included expanded reimbursement and coverage for its glaucoma and dry eye procedures, and FDA 510(k) clearance for the OMNI Ultra Surgical System.
Sight Sciences (Nasdaq: SGHT) announced that Aetna’s updated Glaucoma Surgery Policy for commercial plans now recognizes the OMNI Surgical System and SION Surgical Instrument as medically necessary for treating mild-to-moderate open-angle glaucoma when specified clinical criteria are met.
The policy, retroactive to July 14, 2026, establishes coverage of Sight Sciences’ implant-free, minimally invasive glaucoma surgery technologies, including ab interno canaloplasty (e.g., OMNI) and adult goniotomy (e.g., SION). Aetna covers approximately 25 million total commercial lives in the U.S.
Sight Sciences (Nasdaq: SGHT) received FDA 510(k) clearance for its OMNI Ultra Surgical System for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. OMNI Ultra is the first FDA-cleared MIGS device enabling circumferential canaloplasty in a single pass.
The system adds TruSync Plus technology for controlled viscodilation, preserves the implant-free design, and targets all three conventional outflow resistance sites. According to Sight Sciences, more than 350,000 OMNI procedures have been performed worldwide, and U.S. commercial launch of OMNI Ultra is planned for the fourth quarter of 2026.